InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,625.80
(
0.16%
)
US TECH 100
19,010.00
(
-0.02%
)
Dow Jones
41,250.50
(
0.02%
)
Brent Oil
78.99
(
-1.59%
)
Bitcoin
59,529.90
(
-5.32%
)
Post# of 252980
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120337
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 90616

Monday, 06/03/2013 4:35:39 PM

Monday, June 03, 2013 4:35:39 PM

Post# of 252980
SNY formally kills the Otamixaban (oral FXa-inhibitor) program, which is not surprising. Like PTLA’s Betrixaban (which is still in development but shouldn’t be, IMO), Otamixaban was too little, too late to compete with the likes of Eliquis and Xarelto.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up